Literature DB >> 1919898

Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion.

J H Arnold1, R D Truog, J M Scavone, T Fenton.   

Abstract

Tolerance to opioid-induced sedation has been reported in neonates sedated with fentanyl by continuous infusion while undergoing extracorporeal membrane oxygenation. We undertook a prospective analysis of eight newborn infants sedated with fentanyl during extracorporeal membrane oxygenation therapy for respiratory failure. We recorded daily mean fentanyl infusion rate, measured serial plasma fentanyl concentrations, and documented the occurrence of spontaneous motor activity or respiratory effort. Mean fentanyl infusion rate increased steadily during the period of infusion from a mean of 9.2 +/- 1.9 (SEM) micrograms/kg per hour on day 1 to a mean of 21.9 +/- 4.5 micrograms/kg per hour by day 6. Mean plasma fentanyl concentrations increased steadily during the period of fentanyl infusion from 3.1 +/- 1.1 (SEM) ng/ml on day 1 to 13.9 +/- 3.2 ng/ml on day 6. All infants exhibited movement in response to gentle tactile stimulation throughout the period of infusion, and seven of eight infants manifested spontaneous movement of the extremities and eye opening. Our results indicate that when fentanyl is used for sedation in neonates, the plasma concentrations required for satisfactory sedation steadily escalate, possibly indicating the rapid development of tolerance to the sedating effects of fentanyl.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919898     DOI: 10.1016/s0022-3476(05)82419-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

Review 1.  Assessment and management of pain in neonates.

Authors:  B J Stevens; L S Franck
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.

Authors:  Matteo Di Nardo; Enno Diederick Wildschut
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 3.  Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.

Authors:  Vesa Cheng; Mohd-Hafiz Abdul-Aziz; Jason A Roberts; Kiran Shekar
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Sedation and analgesia in mechanically ventilated preterm neonates: continue standard of care or experiment?

Authors:  Christopher McPherson
Journal:  J Pediatr Pharmacol Ther       Date:  2012-10

5.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

6.  Stress response and procedural pain in the preterm newborn: the role of pharmacological and non-pharmacological treatments.

Authors:  Eloisa Gitto; Salvatore Pellegrino; Maria Manfrida; Salvatore Aversa; Giuseppe Trimarchi; Ignazio Barberi; Russel J Reiter
Journal:  Eur J Pediatr       Date:  2011-12-30       Impact factor: 3.183

Review 7.  Clinical pharmacokinetics of sedatives in neonates.

Authors:  E Jacqz-Aigrain; P Burtin
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

8.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

Review 9.  Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates.

Authors:  Marcia L Buck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Outpatient therapy of iatrogenic drug dependency following prolonged sedation in the pediatric intensive care unit.

Authors:  J D Tobias; J K Deshpande; D F Gregory
Journal:  Intensive Care Med       Date:  1994-08       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.